A New Concern About Weight Loss Drugs: What if They Work Too Well? – The New York Times
https://www.nytimes.com/2026/02/18/well/weight-loss-drugs-retatrutide.html
Posts Tagged ‘glp1’
A New Concern About Weight Loss Drugs: What if They Work Too Well?
February 22, 2026The battle over the trillion-dollar weight-loss bonanza
October 4, 2024https://www.economist.com/business/2024/03/04/the-battle-over-the-trillion-dollar-weight-loss-bonanza glp-1 agonists
QT:{{”
The drugs’ biggest impact so far, though, has been on their makers. Sales of Wegovy, developed by a Danish firm called Novo Nordisk, swelled from $876m in 2022 to $4.5bn in 2023. The company expects double that this year. Zepbound, introduced in America in November by Eli Lilly, an American pharma giant, is expected to generate $2.9bn in sales in its first full year. Bloomberg, a data provider, predicts that by 2030 yearly sales of weight-loss medications will reach a staggering $80bn, putting them among the biggest classes of drugs in history. Eli Lilly and Novo Nordisk are expected to corner more than 90% of the market (see chart 2).
“}}
linkstream2 microblog 